bioAffinity Technologies (BIAF) FCF Margin (2022 - 2026)

bioAffinity Technologies has disclosed FCF Margin across 5 years of filings, most recently posting 239.2% for Q1 2026.

• In Q1 2026, FCF Margin fell 14789.0% year-over-year to 239.2%; the TTM figure through Mar 2026 stood at 193.11% (down 11763.0% YoY), while the FY2025 annual figure was 152.38%, down 7393.0% from the prior year.
• FCF Margin declined to 239.2% in Q1 2026, from 160.69% in the prior quarter.
• Over the last five years, FCF Margin for BIAF reached as high as 65.09% in Q2 2024 and fell as low as 169528.23% in Q1 2023.
• The 5-year median for FCF Margin is 190.43% (2025), against an average of 25968.94%.
• Annual changes were most pronounced in 2024 — FCF Margin jumped 16942902 bps — and 2026, when it slumped 14789 bps.
• A 5-year view of FCF Margin shows it stood at 55440.58% in 2022, then surged by 100 bps to 72.42% in 2023, then decreased by 5 bps to 75.97% in 2024, then plunged by 112 bps to 160.69% in 2025, then sank by 49 bps to 239.2% in 2026.
• According to Business Quant data, FCF Margin over the past three periods registered 239.2%, 160.69%, and 171.27% for Q1 2026, Q4 2025, and Q3 2025 respectively.